Parexel, a provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health, from Clinical through Commercialization, has announced the opening of a new collaboration hub location within the Cambridge Innovation Center (CIC) in Cambridge, Mass. The new space will provide an ideal location for connection and collaboration with customers and employees working in Cambridge and Kendall Square.
“Cambridge is truly a hub for the life sciences industry,” said James Anthony, Senior Vice President and Global Head, Parexel Biotech. “With the continued growth of Parexel Biotech, we are seeing demand for our employees and customers to be in this area on a regular basis. The CIC presence provides us an opportunity to foster closer collaboration with our customers and provides our employees a convenient base of operations in this innovative and vibrant community.”
Parexel Biotech provides tailored solutions to the unique challenges faced by today’s biotech companies, from meeting clinical development timelines to optimizing product and pipeline value to navigating complex regulatory and reimbursement landscapes. The team provides life sciences companies strategic guidance based on years of industry experience combined with clinical and commercial services delivered through lean operational structures that are personalized to their needs and therapeutic specialty.
The Cambridge location will operate as a satellite location and will complement Parexel’s corporate headquarters, which is relocating to Newton, Mass. Earlier this month, Parexel convened the first meeting of its Patient Advisory Council, an initiative intended to drive innovation in drug development leveraging the patient perspective, in the Cambridge hub. Parexel announced the establishment of a second headquarters in its Durham, North Carolina location earlier this year.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.